1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Verastem, Inc.

Verastem, Inc.

VSTM
Verastem, Inc.US flagNASDAQ Global Market
7.70
USD
-0.20
- -
676.63MMarket Cap
Verastem, Inc.
VSTM
(NASDAQ Global Market)

Recent

price

7.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
4.94
2.81
6.93
0.14
0.16
- -
0.28
0.45
0.97
Revenue per Share
-8.13
-20.45
-21.8
-24.82
-19.32
-11.82
-21.18
-13.38
-24.01
-5.3
-4.9
-4.57
-3.96
-3.66
-3.02
-2.24
Basic EPS, GAAP
-6.02
-14.65
-13.95
-18.29
-15.29
-9.58
-17.9
-18.11
-22.29
-2.62
-3.69
-3.95
-3.92
-2.93
-2.12
-1.81
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-7.57
53.31
55.64
39.08
33.29
23.45
13.63
20.21
1.07
8.12
5.67
2.84
2.27
-0.65
0.74
0.55
Book Value per Share
-7.57
53.31
55.64
39.08
33.29
23.45
13.63
16.7
-1.92
8.12
5.67
2.84
2.27
-0.65
0.52
0.38
Tangible Book Value per Share
2
2
2
2
3
3
3
5
6
13
15
16
22
36
69
91
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
27
17
89
2
3
- -
10
31
88
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
-354.75
-758.14
-55.76
-2,991.18
-2,809.59
- -
-1,149.56
-550.33
-182.57
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
2
1
- -
- -
- -
- -
1
1
Depreciation Expense
-14
-32
-41
-53
-58
-36
-68
-72
-149
-68
-71
-74
-87
-131
-209
-203
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
-271.11
-854.77
-76.51
-3,468.1
-2,843.3
- -
-1,306.37
-677.59
-231.59
Profit Margin (%)
45
55
94
86
101
70
71
216
55
128
87
71
117
64
151
98
Working Capital
- -
- -
- -
- -
- -
- -
15
115
107
22
3
26
41
41
81
78
LT Debt
55
90
117
89
102
72
58
124
7
115
88
47
57
-29
57
50
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-39.63
-51.76
-60.52
-41.7
-104.33
-79.61
-226.98
-110.62
-70.21
-109.39
-166.79
- -
- -
-471.16
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6
6
6
LT Borrowings
81
77
76
LT Finance Leases
- -
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
88
90
Market Capitalization
600
466
346

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
223
203
176
Cash, Cash Equivalents & STI
214
182
136
Accounts Receivable, Net
- -
10
29
Inventories
2
2
2
Total Current Liabilities
72
67
78
Payables & Accruals
56
53
66
ST Debt
6
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
98.12%
-99.43%
-297.96%
Free Cash Flow
27.13%
35.22%
40.4%
Net Income, GAAP
24.43%
27.41%
60.35%
Sales/Revenue/Turnover
- -
- -
209.14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
10
- -
- -
10
2025
- -
2
11
18
31
2026
19
40
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.26
-0.31
-0.6
- -
-3.66
2025
-0.96
-0.39
-1.35
- -
-3.02
2026
-0.37
-0.35
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Verona Pharma plc (VRNA)
Synlogic, Inc. (SYBX)
Orthocell Limited (OCC.AX)
InnoCare Pharma Limited (INCPF)
Oncimmune Holdings plc (ONC.L)
Biodexa Pharmaceuticals Plc (BDRX)
Business
Verastem, Inc. Verastem, Inc. (VSTM) is a late-stage biopharmaceutical company focused on developing and commercializing novel small molecule drugs targeting the RAS/MAPK signaling pathway in cancer, including RAF/MEK inhibition via avutometinib, FAK inhibition via defactinib, and KRAS G12D inhibition via VS-7375; the company advances these assets in monotherapy and combinations for low-grade serous ovarian cancer (LGSOC), pancreatic cancer, non-small cell lung cancer, colorectal cancer, and other RAS/MAPK-driven solid tumors, supported by investigator-sponsored trials and combinations with agents such as paclitaxel, pegylated liposomal doxorubicin, letrozole, anastrozole, and cetuximab. Founded in 2010 and headquartered in Needham, Massachusetts, Verastem operates primarily in the United States with a global development strategy through partnerships, employing approximately 78 people under CEO Daniel Paterson. In recent developments, the U.S. FDA approved the avutometinib plus defactinib combination (AVMAPKI FAKZYNJA) as the first therapy for adult patients with KRAS-mutant recurrent LGSOC, with commercialization underway following a planned mid-2025 launch; the company refinanced debt with Oberland Capital, entered a strategic commercialization partnership with IQVIA, completed a $75 million private placement, advanced the GenFleet Therapeutics collaboration with Phase 1/2 initiation of VS-7375 (GFH375) in July 2024 after Chinese IND approval in June 2024, and outlined 2025 priorities including RAMP trials and pipeline expansion.

Company News

Company News APIChatGPT

  • businesswire.com

    Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026

  • defenseworld.net

    Head to Head Survey: Verastem (NASDAQ:VSTM) & Sangamo Therapeutics (NASDAQ:SGMO)

  • businesswire.com

    Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

  • businesswire.com

    Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

  • defenseworld.net

    Verastem (NASDAQ:VSTM) Shares Up 7.1% – Time to Buy?

  • marketbeat.com

    Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright

  • defenseworld.net

    Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of “Moderate Buy” by Brokerages

  • defenseworld.net

    Bank of New York Mellon Corp Makes New Investment in Verastem, Inc. $VSTM

  • zacks.com

    Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

  • businesswire.com

    Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

  • businesswire.com

    Verastem Oncology to Participate in Upcoming September Investor Conferences

  • seekingalpha.com

    Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform

  • defenseworld.net

    Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of “Moderate Buy” from Analysts

  • marketbeat.com

    Verastem Q2 Earnings Call Highlights

  • seekingalpha.com

    Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

  • zacks.com

    Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

  • businesswire.com

    Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

  • businesswire.com

    Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

  • businesswire.com

    Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

  • businesswire.com

    Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer